ijms-logo

Journal Browser

Journal Browser

New Advances in Aquaporinopathy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 4726

Special Issue Editors


E-Mail
Guest Editor
Department of Nephrology, and Cellular and Structural Physiology Laboratory, Tokyo Medical and Dental University, Tokyo 113-8519, Japan
Interests: aquaporin; kidney transporters; kidney channels, water and electrolyte metabolism; diabetes insipidus; hereditary kidney diseases

E-Mail
Guest Editor
1. Department of Nephrology, Nitobe Memorial Nakano General Hospital, Tokyo 164-8607, Japan
2. Department of Nephrology, Tokyo Medical and Dental University, Tokyo 113-8519, Japan
Interests: aquaporin; membrane protein trafficking; kidney transporters; water and electrolyte metabolism; diabetes insipidus; chronic kidney disease

Special Issue Information

Dear Colleagues,

The first aquaporin (AQP) was discovered as a water channel protein of human red blood cell, but many of later AQP members permeate not only water but many small solutes, ions (chloride and nitrate), arsenate, boron, silicon and even gases (CO2, NH3 and NO). Beyond these heterogeneities in channel function, functions other than channel have been discovered, such as cell membrane adhesion (AQP4), signal transduction (AQP2), stimulator of cell migration and wound recovery (AQP1, 3), trigger of auto-immune system (AQP4) and mediator of inflammation (AQP3). However, until now, aquaporinopathy which includes diseases and disordered conditions caused by AQP's disfunction is recognized in a limited spectrum of diseases. Typical examples are hereditary nephrogenic diabetes insipidus (AQP2), congenital cataract (AQP1), neuromyelitis optica (AQP4) , obesity (AQP7) and Sjogren’s syndrome (AQP5). There are 13 members of AQP in human and they are conserved through the evolution, implying that they play indispensable roles for survival that are easily overlooked in comfortable environment in modern life. Understanding aquaporinopathy is anticipated to reveal novel therapeutic targets in many diseases. This special issue will welcome papers focusing on AQP-related diseases and abnormal states, and their pathophysiologies.

Prof. Sei Sasaki
Dr. Yumi Noda
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Aquaporin
  • AQP
  • aquaporinopathy
  • nephrogenic diabetes insipidus
  • neuromyelitis optica
  • congenital cataracta
  • obesity
  • kidney
  • brain edema
  • water transport

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

16 pages, 865 KiB  
Review
Updates and Perspectives on Aquaporin-2 and Water Balance Disorders
by Yumi Noda and Sei Sasaki
Int. J. Mol. Sci. 2021, 22(23), 12950; https://doi.org/10.3390/ijms222312950 - 30 Nov 2021
Cited by 20 | Viewed by 4075
Abstract
Ensuring the proper amount of water inside the body is essential for survival. One of the key factors in the maintenance of body water balance is water reabsorption in the collecting ducts of the kidney, a process that is regulated by aquaporin-2 (AQP2). [...] Read more.
Ensuring the proper amount of water inside the body is essential for survival. One of the key factors in the maintenance of body water balance is water reabsorption in the collecting ducts of the kidney, a process that is regulated by aquaporin-2 (AQP2). AQP2 is a channel that is exclusively selective for water molecules and impermeable to ions or other small molecules. Impairments of AQP2 result in various water balance disorders, including nephrogenic diabetes insipidus (NDI), which is a disease characterized by a massive loss of water through the kidney and consequent severe dehydration. Dysregulation of AQP2 is also a cause of water retention with hyponatremia in heart failure, hepatic cirrhosis, and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Antidiuretic hormone vasopressin is an upstream regulator of AQP2. Its binding to the vasopressin V2 receptor promotes AQP2 targeting to the apical membrane and thus enables water reabsorption. Tolvaptan, a vasopressin V2 receptor antagonist, is effective and widely used for water retention with hyponatremia. However, there are no studies showing improvement in hard outcomes or long-term prognosis. A possible reason is that vasopressin receptors have many downstream effects other than AQP2 function. It is expected that the development of drugs that directly target AQP2 may result in increased treatment specificity and effectiveness for water balance disorders. This review summarizes recent progress in studies of AQP2 and drug development challenges for water balance disorders. Full article
(This article belongs to the Special Issue New Advances in Aquaporinopathy)
Show Figures

Figure 1

Back to TopTop